Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study showed the long-term benefit of SYFOVRE (pegcetacoplan injection) for geographic atrophy/GA secondary to age-related macular degeneration/AMD.

Following 5 years of continuous treatment, the data showed that both monthly and every-other-month administration of SYFOVRE delayed GA lesion growth by ~1.5 years in patients with non-subfoveal GA when compared to sham/projected sham. This is significant because GA is a progressive and irreversible disease caused by growing lesions that destroy retinal cells and is a leading cause of blindness worldwide, impacting over 1 million Americans and 5 million people globally.

Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy

SYFOVRE (pegcetacoplan injection) is the first-ever FDA-approved therapy for geographic atrophy, working by targeting C3 to provide comprehensive control of the complement cascade. It is indicated for the treatment of GA secondary to age-related macular degeneration in the US. SYFOVRE is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, and those with hypersensitivity to pegcetacoplan.

Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds to treat diseases with high unmet needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.